Medicare Advantage enrollees whose plans exit the market at the end of 2026 will be shifted back to Original Medicare, but federal rules guarantee them the right to buy a Medigap supplemental policy without medical underwriting or denial. CMS has stated that beneficiaries whose Medicare managed care plans leave the program have a guaranteed right to buy certain Medigap plans. The Contract Year 2027 Medicare Advantage and Part D Final Rule, combined with existing notice requirements under federal regulation, sets the stage for how affected enrollees will learn about and act on that protection.
How 2027 MA contract exits trigger Medigap protections
Every Medicare Advantage contract ends on Dec. 31, according to federal rules. When a plan does not renew its contract or reduces its service area, the regulation requires the insurer to send affected enrollees a non-renewal notice that spells out their options, including their right to purchase Medigap coverage on guaranteed-issue terms. That means no health screening, no denial for pre-existing conditions, and no waiting periods for the specific plans covered by the protection.
The practical consequence is straightforward: an enrollee who did nothing wrong and simply had a plan disappear gets a federally backed window to lock in supplemental coverage. Without that window, someone with serious health conditions could face steep premiums or outright rejection from Medigap insurers in states that allow medical underwriting outside of open enrollment periods. The guaranteed-issue right removes that barrier entirely for qualifying individuals.
These protections are especially important for beneficiaries who have relied on an MA plan to cap their out-of-pocket costs. Original Medicare does not include an annual maximum on Part A and Part B cost-sharing, so a Medigap policy often becomes the main tool for limiting financial exposure after an MA exit. When the contract ends, the guaranteed-issue window allows eligible beneficiaries to move quickly into standardized Medigap options without worrying that a recent diagnosis or hospitalization will make them uninsurable.
CMS rulemaking and notice standards for contract year 2027
CMS issued the Contract Year 2027 Medicare Advantage and Part D Final Rule, which shapes the broader policy environment for the upcoming contract year. The regulation at 42 CFR Section 422.2267 governs the specific language plans must include in enrollee notices for non-renewals and service area reductions, with provisions designed to ensure consistent application of Medigap guaranteed-issue rights. In practice, this means plans must clearly explain that affected members can return to Original Medicare and may qualify for a special right to buy certain Medigap plans.
The hypothesis that stricter notice language alone will produce measurably higher Medigap enrollment rates among affected beneficiaries is plausible but unproven. No primary CMS dataset yet lists specific 2027 MA contract non-renewals or service-area reductions by county, and the Federal Register text for the CY 2027 rule does not include state-by-state Medigap guaranteed-issue uptake data. What the regulatory framework does accomplish is a clearer disclosure obligation: plans must tell departing members exactly what protections exist and how to act on them.
State insurance regulators reinforce this federal framework. Washington state’s Office of the Insurance Commissioner, for example, confirms that moving to Original Medicare plus a Medigap policy is the standard path when an MA contract ends. CMS maintains a centralized Medigap page that consolidates guidance documents, including the “Choosing a Medigap Policy” guide and related Q&A materials developed with the National Association of Insurance Commissioners. These materials emphasize that contract terminations are one of the qualifying events that can trigger guaranteed-issue rights.
Enrollment timelines and beneficiary decisions
When an MA contract is not renewed, affected enrollees generally have a limited window to make coverage decisions. They are typically moved to Original Medicare if they take no action, but the guaranteed-issue right to buy Medigap coverage is time-limited. During this period, beneficiaries can compare standardized Medigap plans, assess premiums, and decide whether to add a standalone Part D prescription drug plan to replace the drug coverage that may have been embedded in their MA plan.
CMS directs consumers to official Medigap buying information that walks through the steps of contacting insurers, confirming eligibility for guaranteed-issue protections, and completing enrollment before the window closes. The guidance stresses that waiting too long can mean losing the special right and being subject to medical underwriting in most states. For people with chronic conditions, that timing can be the difference between affordable coverage and being priced out of the market.
Beneficiaries also must weigh whether to remain in the Medicare Advantage program by choosing a different MA plan during the special enrollment period. In counties with robust MA competition, switching to another plan may preserve familiar managed care features such as provider networks and extra supplemental benefits. In areas with fewer alternatives, however, moving to Original Medicare plus a Medigap policy may offer more predictable access to providers and fewer prior authorization hurdles.
What to watch as 2026 contracts wind down
As 2026 draws to a close, the key indicators will be how clearly insurers communicate non-renewals, how quickly beneficiaries receive their notices, and whether consumer assistance programs are equipped to explain Medigap rights in plain language. Advocates and regulators will likely monitor complaint data and call volumes to see whether people understand that they can obtain Medigap coverage without medical underwriting when their MA plan exits.
For now, the combination of CMS rulemaking, federal notice standards, and state-level oversight creates a defined pathway from a terminated Medicare Advantage contract back to Original Medicare with the option of guaranteed-issue Medigap coverage. The policy challenge ahead is ensuring that every affected enrollee not only has that right on paper but also receives timely, actionable information to use it before the window closes.
